C. Crowther, P. Ashwood, P. F. Middleton, A. McPhee, T. Tran, J.E. Harding
{"title":"妊娠 30 至 34 周时的产前静脉注射镁与后代的神经发育结果：MAGENTA 随机临床试验","authors":"C. Crowther, P. Ashwood, P. F. Middleton, A. McPhee, T. Tran, J.E. Harding","doi":"10.1097/01.aoa.0001016052.26395.51","DOIUrl":null,"url":null,"abstract":"(JAMA. 2023;330(7):603–614)\n Preterm infants have a greater risk of cerebral palsy, a common motor disability for which there is no cure. As such, primary prevention is especially important. The use of magnesium sulfate while pregnant has been shown in randomized clinical trials to be helpful for those at risk of early preterm delivery by improving an infant’s chance of survival without cerebral palsy. As a result, magnesium sulfate is recommended for fetal neuroprotection. However, there is a lack of data surrounding the ideal gestational age for using it prenatally.","PeriodicalId":19432,"journal":{"name":"Obstetric Anesthesia Digest","volume":"16 9","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prenatal Intravenous Magnesium at 30 to 34 Weeks’ Gestation and Neurodevelopmental Outcomes in Offspring: The MAGENTA Randomized Clinical Trial\",\"authors\":\"C. Crowther, P. Ashwood, P. F. Middleton, A. McPhee, T. Tran, J.E. Harding\",\"doi\":\"10.1097/01.aoa.0001016052.26395.51\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"(JAMA. 2023;330(7):603–614)\\n Preterm infants have a greater risk of cerebral palsy, a common motor disability for which there is no cure. As such, primary prevention is especially important. The use of magnesium sulfate while pregnant has been shown in randomized clinical trials to be helpful for those at risk of early preterm delivery by improving an infant’s chance of survival without cerebral palsy. As a result, magnesium sulfate is recommended for fetal neuroprotection. However, there is a lack of data surrounding the ideal gestational age for using it prenatally.\",\"PeriodicalId\":19432,\"journal\":{\"name\":\"Obstetric Anesthesia Digest\",\"volume\":\"16 9\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Obstetric Anesthesia Digest\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/01.aoa.0001016052.26395.51\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetric Anesthesia Digest","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/01.aoa.0001016052.26395.51","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Prenatal Intravenous Magnesium at 30 to 34 Weeks’ Gestation and Neurodevelopmental Outcomes in Offspring: The MAGENTA Randomized Clinical Trial
(JAMA. 2023;330(7):603–614)
Preterm infants have a greater risk of cerebral palsy, a common motor disability for which there is no cure. As such, primary prevention is especially important. The use of magnesium sulfate while pregnant has been shown in randomized clinical trials to be helpful for those at risk of early preterm delivery by improving an infant’s chance of survival without cerebral palsy. As a result, magnesium sulfate is recommended for fetal neuroprotection. However, there is a lack of data surrounding the ideal gestational age for using it prenatally.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
